Abstract: Objective: To evaluate the efficacy and safety of deucravacitinib in the treatment of moderate-to-severe plaque psoriasis. Methods: The related literature were searched in Pubmed, Cochrane Library, Embase, CNKI, VIP, Wanfang and clinicaltrials.gov. All randomized controlled trials (RCT) that meet the requirements were collected. Meta-analysis was performed after extracting the data. Results: A total of four RCTs were included,including 1996 patients with moderate-to-severe plaque psoriasis. Meta-analysis showed that the rate of patients in the deucravacitinib group who reached various efficacy indicators (PASI 75, sPGA 0/1, PASI 90, PASI 100, DLQI 0/1) were significantly higher than that in the placebo group or the apremilast group after 16 or 24 weeks of treatment (P<0.05); the rate of patients in the deucravacitinib group who reached various efficacy indicators (PASI 75, sPGA 0/1, PASI 90, PASI 100, DLQI 0/1) were still significantly higher than that in the apremilast group after 24 weeks of treatment (P<0.05). The incidence of total adverse events in the deucravacitinib group was higher than that in the placebo group (P<0.05), which was comparable to the apremilast group (P＞0.05). There was no statistical difference in the incidence of serious adverse events between the deucravacitinib group and the placebo group or the apremilast group (P＞0.05). Conclusion: Deucravacitinib is superior to both placebo and apremilast in treating moderate-to-severe plaque psoriasis, and adverse effects are well tolerated.

Key words: deucravacitinib, plaque psoriasis, meta-analysis